SKYE Class Action Reminder: Skye Bioscience, Inc. Stockholders Should Contact Robbins LLP for Information About the Securities Class Action Lawsuit

SAN DIEGO, Dec. 2, 2025 /PRNewswire/ -- Company: Skye Bioscience, Inc. (NYSE: SKYE) is a clinical stage biopharmaceutical company that focuses on developing molecules that modulate G protein-coupled receptors ("GPCRs") to treat obesity, overweight, and metabolic diseases. The Company's lead product candidate is nimacimab.

Read more at prnewswire.com